Thermohydrogel Containing Melanin for Photothermal Cancer Therapy

Melanin is an effective absorber of light and can extend to near infrared (NIR) regions. In this study, a natural melanin is presented as a photothermal therapeutic agent (PTA) because it provides a good photothermal conversion efficiency, shows biodegradability, and does not induce long‐term toxici...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Macromolecular bioscience 2017-05, Vol.17 (5), p.n/a
Hauptverfasser: Kim, Miri, Kim, Hyun Soo, Kim, Min Ah, Ryu, Hyanghwa, Jeong, Hwan‐Jeong, Lee, Chang‐Moon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Melanin is an effective absorber of light and can extend to near infrared (NIR) regions. In this study, a natural melanin is presented as a photothermal therapeutic agent (PTA) because it provides a good photothermal conversion efficiency, shows biodegradability, and does not induce long‐term toxicity during retention in vivo. Poloxamer solution containing melanin (Pol–Mel) does not show any precipitation and shows sol–gel transition at body temperature. After irradiation from 808 nm NIR laser at 1.5 W cm−2 for 3 min, the photothermal conversion efficiency of Pol–Mel is enough to kill cancer cells in vitro and in vivo. The tumor growth of mice bearing CT26 tumors treated with Pol–Mel injection and laser irradiation is suppressed completely without recurrence postirradiation. All these results indicate that Pol–Mel can become an attractive PTA for photothermal cancer therapy. Poloxamer solution containing melanin (Pol–Mel) shows sol–gel transition at body temperature after heat generation induced by near infrared 808 nm laser irradiation. Following intratumoral injection of Pol–Mel and the laser irradiation, the growth of the CT26 tumors is suppressed completely without recurrence. From these results, Pol–Mel is a potentially attractive photothermal therapeutic agent for cancer therapy.
ISSN:1616-5187
1616-5195
DOI:10.1002/mabi.201600371